Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, USA.
, Beachwood, USA.
J Gen Intern Med. 2020 Nov;35(11):3271-3277. doi: 10.1007/s11606-020-06170-w. Epub 2020 Sep 14.
Black elderberry, used medicinally for centuries, decreased influenza duration by 4 days in three previous peer-reviewed trials. US elderberry sales, possibly related to a "high severity" and "high activity" influenza season from January to March 2018, more than doubled from 2017 to 2018 to > $100 million.
To determine whether elderberry extract decreases influenza's duration and severity.
FDA-approved, investigator-initiated, Investigational New Drug, double-blind, randomized, placebo-controlled trial. Conducted January 2018-April 2019 in three emergency rooms, two suburban and one urban, in the Midwestern Health System.
Eighty-seven consecutive, consenting patients, over age four, with < 48 h of at least 2 moderate-severity influenza symptoms and positive polymerase chain reaction influenza test.
Patients from age 5 to 12 years received placebo or 15 ml (5.7 g) elderberry extract orally twice a day for 5 days; those > 12 years received 15 ml 4 times a day for 5 days. Patients were permitted to choose to also receive the standard dosage of oseltamivir.
Primary: days until all symptoms were none or mild for 21.5 h. Secondary: days to complete symptom resolution for 24 h.
The 87 participants were randomized to receive placebo (n = 44) or elderberry (n = 43). The average age was 25 ± 20 years, and 56% were male. The average number of days to reach all symptoms none or mild for 21.5 h in the placebo group was 4.9 ± 2.8 days compared to 5.3 ± 3.6 in the elderberry group (p = 0.57). The average number of days to complete resolution was 8.7 ± 3.8 and 8.6 ± 3.9 in the placebo and elderberry group, respectively (p = 0.87).
Small sample size, but powered > 0.90 to detect 2-day benefit of elderberry versus placebo.
We found no evidence that elderberry benefits the duration or severity of influenza. Post hoc analysis suggested primary outcomes with elderberry taken alone (without oseltamivir) were 2 days worse than with placebo taken alone. Our results contradict previous studies and demonstrate the need for further studies.
NCT03410862.
黑接骨木,几个世纪以来一直被用于医学,在之前的三项同行评审试验中,将流感持续时间缩短了 4 天。2018 年 1 月至 3 月,美国接骨木的销售额可能与“高严重性”和“高活动”的流感季节有关,与 2017 年相比翻了一番多,达到 >1 亿美元。
确定接骨木提取物是否能缩短流感的持续时间和严重程度。
FDA 批准,由研究者发起,研究性新药,双盲,随机,安慰剂对照试验。于 2018 年 1 月至 2019 年 4 月在中西部卫生系统的两个郊区和一个城市的三个急诊室进行。
87 名连续同意的患者,年龄在 4 岁以上,有<48 小时至少 2 种中度至重度流感症状和聚合酶链反应流感检测阳性。
5 至 12 岁的患者口服安慰剂或 15 毫升(5.7 克)接骨木提取物,每日两次,连续 5 天;年龄>12 岁的患者每天服用 4 次,每次 15 毫升,连续 5 天。允许患者选择同时服用标准剂量的奥司他韦。
主要:所有症状无或轻度缓解的天数为 21.5 小时。次要:完成症状缓解的天数为 24 小时。
87 名参与者被随机分配至接受安慰剂(n=44)或接骨木组(n=43)。平均年龄为 25±20 岁,56%为男性。在安慰剂组中,达到所有症状无或轻度缓解的 21.5 小时的平均天数为 4.9±2.8 天,而接骨木组为 5.3±3.6 天(p=0.57)。完成缓解的平均天数分别为 8.7±3.8 和 8.6±3.9 天,安慰剂组和接骨木组分别为 8.7±3.8 和 8.6±3.9 天(p=0.87)。
样本量小,但>0.90 有足够的效力检测接骨木与安慰剂相比的 2 天益处。
我们没有发现接骨木对流感的持续时间或严重程度有任何益处的证据。事后分析表明,单独使用接骨木(不使用奥司他韦)的主要结果比单独使用安慰剂差 2 天。我们的结果与之前的研究相矛盾,表明需要进一步研究。
NCT03410862。